sars-cov-2

Documents about sars-cov-2

• A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae#880879ClinicalTrials.gov
• WHO Declares COVID-19 a Pandemic.#6166OpenAlex
• Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads#383523ClinicalTrials.gov
• Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.#864641ClinicalTrials.gov
• A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care#847440ClinicalTrials.gov
• Prevalence of Alpha-Synuclein Seeding Activity in the Olfactory Mucosa following SARS-CoV-2 Infection - Results from a Pilot Study#4953Europe PMC
• Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan#11922DataCite
• Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan#11923DataCite
• Modernising antiviral drug discovery: harnessing medicinal plants through machine learning and metabolomics to target the SARS-CoV-2 main protease.#30571NCBI PubMed Central
• Microtesla Magnetic Therapy for cognitive impairment in post-acute sequelae of SARS CoV-2: A randomized controlled feasibility study#68019bioRxiv / medRxiv
• Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults#121472ClinicalTrials.gov
• Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)#125910ClinicalTrials.gov
• Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19#143660ClinicalTrials.gov
• Integrative multi-omics analysis reveals microbiota alterations and clinical indicators predictive of pulmonary fibrosis progression following SARS-CoV-2 infection.#148187NCBI PubMed Central
• A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19#152500ClinicalTrials.gov
• Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)#174939ClinicalTrials.gov
• The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.#180211ClinicalTrials.gov
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals#234472ClinicalTrials.gov
• SARS-CoV-2 virus infection of Peromyscus leucopus demonstrates that infection tolerance is not limited to agents for which deermice are reservoirs#245291bioRxiv / medRxiv
• Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)#253072ClinicalTrials.gov
• Association of IL6 Gene Polymorphisms with COVID-19 Susceptibility and Inflammation in Pregnant Women#280370HAL (France)
• Wastewater Surveillance as an Event Detection System: Outbreak and Peak Detection of SARS-CoV-2 Across 281 U.S. Counties#287268bioRxiv / medRxiv
• Applying a NIOSH Industry and Occupation Coding tool to evaluate occupational risk of SARS-CoV-2 infection in pregnant women.#301627NCBI PubMed Central
• Walking the path: exploring the pathways of emerging viral diseases#325973HAL (France)
• Computational and Experimental Antibody Affinity and Diagnostic Accuracy Quantification of SARS-CoV-2 SD2 Major Disulfide Loop Analog#346692bioRxiv / medRxiv
• Replication Data for: Optimizing Peptide Inhibitors of SARS-Cov-2 nsp10/nsp16 Methyltransferase Predicted through Molecular Simulation and Machine Learning#377864George Mason University Dataverse Dataverse OAI Archive
• Unravelling the genomic and epidemiological dynamics of SARS-CoV-2 in South Africa.#389791ResearchSpace
• Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine#394625ClinicalTrials.gov
• A Descriptive Pilot Assessment of Simple Outpatient Functional Measures Following SARS-CoV-2 Infection in Adults with Chronic Diseases.#409314NCBI PubMed Central
• A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years#414346ClinicalTrials.gov
• Comparing the Risk of SARS-CoV-2 Immune Resistance Evolving Across Regions in the Americas with Differing Approaches to Public Health.#415555NCBI PubMed Central
• Entry, replication and innate immunity evasion of BANAL-236, a SARS-CoV-2-related bat virus, in Rhinolophus and human cells#417988HAL (France)
• Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19#426626ClinicalTrials.gov
• Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19#426630ClinicalTrials.gov
• The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines#432930ClinicalTrials.gov
• The potential impact of the spreading of highly transmissible Omicron variant XBB.1.5 and JN.1 on the evolution of SARS-CoV-2#435658bioRxiv / medRxiv
• Systematic characterization of SARS-CoV-2 spike protein subunit trafficking and secretion reveals enhanced strategies for vaccine design and quantification.#446218NCBI PubMed Central
• Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination#454072ClinicalTrials.gov
• Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults#633766ClinicalTrials.gov
• Efectos más influyentes de la pandemia “Sars-cov-2” : COVID 19 en los trabajadores de Providencia#647424Repositorio UNAB
• Emergence of the SARS-CoV-2 furin cleavage site in humans is constrained to late 2019: implications for COVID-19 origins#656852arXiv (OAI Expanded)
• Emergence of the SARS-CoV-2 furin cleavage site in humans is constrained to late 2019: implications for COVID-19 origins#658988arXiv (All)
• Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.#801473ClinicalTrials.gov
• Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women#805744ClinicalTrials.gov
• Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic#807054ClinicalTrials.gov
• Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial#827278ClinicalTrials.gov
• Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias#827381ClinicalTrials.gov
• A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19#833022ClinicalTrials.gov
• Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation#836483ClinicalTrials.gov
• Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.#841781ClinicalTrials.gov